FLCN and neoplasm: Afatinib significantly slowed the growth of FTC-133 (FLCN−/−) xenograft tumours compared to the Vehicle-treated tumours (Fig. 6c), suggesting that the increased pEGFR signalling observed in vitro is also important for in vivo growth of FLCN−/− tumours.